Schilsky Richard L, Gordon Gary, Gilmer Tona M, Courtneidge Sara A, Matrisian Lynn M, Grad Oren, Nelson William G
University of Chicago, Chicago, Illinois, USA.
Clin Cancer Res. 2008 Sep 15;14(18):5685-91. doi: 10.1158/1078-0432.CCR-08-1265.
The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the National Cancer Institute's investment in translational research and envision its future. The TRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of agents-both small molecules and biologics-for the treatment and prevention of cancer. The Agents Developmental Pathway was conceived not as a comprehensive description of the corresponding real-world processes, but rather as a tool designed to facilitate movement of an agent through the translational process to the point where it can begin definitive clinical testing. This article presents the Agents Developmental Pathway and discusses key challenges associated with the processes described.
转化研究工作组(TRWG)作为一项全国性倡议而成立,旨在评估美国国立癌症研究所(National Cancer Institute)在转化研究方面的投资现状并展望其未来。TRWG将转化研究概念化为一组六个围绕各种临床目标的发展过程或途径。其中一条途径描述了用于癌症治疗和预防的药物(包括小分子药物和生物制剂)的开发。药物开发途径并非对相应现实世界过程的全面描述,而是旨在促进药物通过转化过程直至能够开始确定性临床试验的一种工具。本文介绍了药物开发途径,并讨论了与所描述过程相关的关键挑战。